Chemomab Therapeutics LTD. (CMMB) — 6-K Filings

All 6-K filings from Chemomab Therapeutics LTD.. Browse 23 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (23)

6-K Filing — Nov 21, 2025
Chemomab Therapeutics Announces ADS Ratio Adjustment — Aug 22, 2025 Risk: low
Chemomab Therapeutics Ltd. announced on August 22, 2025, that it will implement a ratio adjustment for its American Depositary Shares (ADSs) relative to its ord
Chemomab Therapeutics Ltd. Files Form 6-K — Aug 14, 2025 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on August 14, 2025, reporting on its activities for the month of August 2025. The company, previously known as Anchi
Chemomab Therapeutics Ltd. Enters Sales Agreement — Jul 25, 2025 Risk: medium
On July 25, 2025, Chemomab Therapeutics Ltd. entered into a Sales Agreement with LifeSci Capital, LLC. This agreement allows Chemomab to offer and sell its Amer
Chemomab Therapeutics Ltd. Holds Annual Shareholder Meeting — Jul 1, 2025 Risk: low
Chemomab Therapeutics Ltd. held its annual general shareholders meeting on July 1, 2025. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancel
Chemomab Therapeutics Files 6-K for Shareholder Meeting — May 27, 2025 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on May 27, 2025, to furnish a Notice and Proxy Statement for its upcoming annual general meeting of shareholders. Th
Chemomab Therapeutics Reports Q1 2025 Results — May 15, 2025 Risk: medium
Chemomab Therapeutics Ltd. announced its first quarter 2025 financial results and provided a corporate update on May 15, 2025. The company, formerly known as An
Chemomab Therapeutics Announces CMO Departure, Appoints Interim — Apr 15, 2025 Risk: medium
Chemomab Therapeutics Ltd. announced on April 15, 2025, the departure of its Chief Medical Officer, Dr. Matthew Frankel. Concurrently, Dr. David M. Weiner, MD,
Chemomab Therapeutics Reports Positive Phase 2 Nebokitug PSC Trial Results — Mar 27, 2025 Risk: medium
On March 27, 2025, Chemomab Therapeutics Ltd. announced positive results from the open-label extension of its Phase 2 trial for Nebokitug in Primary Sclerosing
Chemomab Therapeutics Files 6-K with Prospectus Supplement Details — Mar 20, 2025 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on March 20, 2025, reporting on a prospectus supplement filed on November 15, 2024, under a Sales Agreement with Rot
Chemomab Therapeutics Reports 2024 Financials & Update — Mar 3, 2025 Risk: medium
Chemomab Therapeutics Ltd. announced its financial results for the year ended and fourth quarter of 2024 on March 3, 2025. The company, formerly known as Anchia
Chemomab Therapeutics Clears FDA Path for Nebokitug — Feb 19, 2025 Risk: medium
On February 19, 2025, Chemomab Therapeutics Ltd. announced the successful completion of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (F
Chemomab Therapeutics Ltd. Holds Special Shareholder Meeting — Nov 18, 2024 Risk: low
Chemomab Therapeutics Ltd. held a special general shareholders meeting on November 18, 2024, to discuss and vote on certain matters. The company, formerly known
Chemomab Therapeutics Q3 2024 Financial Results Filed — Nov 14, 2024 Risk: low
Chemomab Therapeutics Ltd. announced its third quarter 2024 financial results on November 14, 2024. The company, formerly known as Anchiano Therapeutics Ltd. an
Chemomab Therapeutics Calls Special Shareholder Meeting — Oct 11, 2024 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on October 11, 2024, to furnish a Notice and Proxy Statement for a special general meeting of its shareholders. The
Chemomab Therapeutics Files Form 6-K — Aug 21, 2024 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on August 21, 2024, reporting on its activities for the month of August 2024. The company, formerly known as Anchian
Chemomab Therapeutics Ltd. Files 6-K, Details Former Names — Jul 25, 2024 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on July 25, 2024, reporting information as a foreign private issuer. The filing indicates the company was formerly k
Chemomab Therapeutics Holds Annual Shareholder Meeting — Jun 12, 2024 Risk: low
Chemomab Therapeutics Ltd. (the "Company") held its annual general shareholders meeting on June 10, 2024. The company, formerly known as Anchiano Therapeutics L
Chemomab Therapeutics Q1 2024 Update — May 9, 2024 Risk: low
Chemomab Therapeutics Ltd. announced its first quarter 2024 financial results and provided a corporate update on May 9, 2024. The company, formerly known as Anc
Chemomab Therapeutics Files 6-K with Press Release — May 8, 2024 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on May 8, 2024, to furnish a press release dated May 8, 2024. The press release is titled "Chemomab Therape". The co
Chemomab Therapeutics Files Shareholder Meeting Notice — May 3, 2024 Risk: low
Chemomab Therapeutics Ltd. filed a Form 6-K on May 3, 2024, to furnish a Notice and Proxy Statement for its upcoming annual general meeting of shareholders. The
Chemomab Therapeutics Reports 2023 Financials & Corporate Update — Mar 7, 2024 Risk: low
Chemomab Therapeutics Ltd. announced its financial results for the year ended and fourth quarter of 2023 on March 7, 2024. The company, formerly known as Anchia
Chemomab Completes CM-101 PSC Trial Enrollment, Topline Data Mid-2024 — Jan 3, 2024
Chemomab Therapeutics Ltd. announced on January 3, 2024, the successful completion of patient enrollment for its CM-101 Phase 2 clinical trial targeting Primary

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX